ESTRO 2024 - Abstract Book

S1195

Clinical - Head & neck

ESTRO 2024

4. Mohamed ASR, Rosenthal DI, Awan MJ, et al. Methodology for analysis and reporting patterns of failure in the era of IMRT: head and neck cancer applications. Radiat Oncol. 2016;11:95.

5. Raktoe SAS, Dehnad H, Raaijmakers CPJ, Braunius W, Terhaard CHJ. Origin of tumor recurrence after intensity modulated radiation therapy for oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2013;85:136 141.

442

Poster Discussion

Is comorbidity associated with interruption of Radiotherapy treatment in patients with HNSCC cancer?

Azadeh Abravan 1,2 , Eliana Vasquez osorio 1,2 , James Price 2 , Marcel van Herk 1,2 , Hitesh Mistry 1 , Gareth Price 1,2

1 University of Manchester, Division of Cancer Sciences, Manchester, United Kingdom. 2 Christie NHS Foundation Trust, Radiotherapy Related Research, Manchester, United Kingdom

Purpose/Objective:

Radiotherapy (RT) plays an important role in the management of patients with cancer. Timely completion of treatment has been shown to predict treatment outcome, including overall survival (OS)1. Comorbidity may affect the risk of treatment completion2. However, the degree to which comorbidity burden affects RT interruption is not fully understood. In this study we investigated whether RT completion is associated with OS and furthermore if overall score comorbidities and baseline comorbidities are associated with RT completion in a large cohort of head and neck squamous cell carcinoma (HNSCC) cancer patients.

Material/Methods:

Data were collected from 1,877 HNSCC patients treated at a single institute with curative-intent RT (60/63/66 Gy in 30 fractions, with/without concurrent or sequential chemotherapy) between January 2013 and February 2023 and for whom Adult Co-Morbidity Evaluation (ACE-27) scores3 were available. RT was given to patients on weekdays over six weeks. Overall treatment duration (days) was defined as the number of weekdays from treatment initiation to the last fraction received. ACE-27 comorbidities at diagnosis were considered as binary variables (with/without comorbidity). Overall comorbidity scores were considered as none, mild, moderate, and severe. Treatment completion was categorized into three groups, patients who did not complete the treatment, those who completed the treatment in the scheduled 30 days, and those who completed the treatment after more than 30 days (late completion). The association of treatment completion and OS was assessed via a multivariable Cox regression model. The association of treatment completion category with different comorbidities and overall comorbidity score was assessed via individual multinomial logistic regression models. All models were adjusted for age, gender, performance status, gross tumour volume (in logarithmic scale), chemotherapy and multiple deprivation index (IMD). IMD deciles are calculated by ranking geographic areas of the UK from most to least deprived and dividing them into 10 equal groups (decile 1, most deprived 10%; decile 10, least deprived 10%).